1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Genentech’s PFS Data May Help Inavolisib Compete In PI3KCA-Mutated Breast Cancer

 
• By Joseph Haas

Inavolisib meets statistical significance for progression-free survival in HR+/HER2- advanced breast cancer with a PI3KCα mutation, which could set up competition with Piqray, Ibrance and Kisqali.

Genetech
Genentech's inavolisib may offer a new treatment option in HR+/HER2- breast cancer • Source: Shutterstock: Michael Vi

Genentech, Inc. may have taken a strategically important step in the treatment of HR+/HER2- advanced breast cancer with a PI3KCA mutation on 5 December with pivotal data showing that its inavolisib can provide statistically significant progression-free survival (PFS) versus a comparator regimen.

Key Takeaways

  • Genentech’s inavolisib demonstrates a progression-free survival benefit in HR+/HER2-negative breast cancer.

While the Roche Holding AG division did not share numerical data from the Phase III INAVO120 study, Genentech announced...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Where Next For Biologics In COPD After Roche’s Astegolimab Phase III Missfire?

 
• By Sushmita Panda

The Phase III failure could dent Roche’s hopes of entering the COPD market with its novel therapy, despite its success in a large Phase IIb trial. It also marks another disappointment for the anti-IL33/ST2 approach.

Abivax Over The Moon As Obefazimod Storms Phase III

 
• By Kevin Grogan

Stock shoots up over 460% on positive results in two ulcerative colitis trials of the oral first-in-class candidate.

The Duchenne Gene Therapies Lining Up To Take Elevidys’ Place

 
• By Andrew McConaghie

Regenxbio and Solid Biosciences believe they have a next-generation approach to AAV-based gene therapies – but must distance themselves from Sarepta’s safety and efficacy problems.

Replimune CRL Could Hold Warning For Accelerated Approvals

 
• By Jessica Merrill

FDA issued a complete response letter to Replimune’s BLA for a novel oncolytic immunotherapy for melanoma in a surprise to management and investors.

More from R&D